Lin BioScience, Inc. (銵?鋆蔭?詨) is a leading drug development company founded in 2016. With a focus on addressing unmet medical needs, Lin BioScience is dedicated to developing novel therapies and first-in-class treatments in therapeutic areas such as ophthalmology, oncology, and metabolic diseases.

The company's pipeline consists of four promising candidate drugs. LBS-008 is being developed to treat dry age-related macular degeneration and Stargardt disease, while LBS-009 targets nonalcoholic steatohepatitis. These two drugs are developed by Lin BioScience's subsidiary, Belite Bio Inc.

(Nasdaq: BLTE). Lin BioScience, Inc. Additionally, LBS-002 aims to address glioblastoma and its metastasis.

Under the leadership of a highly experienced management team, Lin BioScience is committed to delivering breakthrough therapeutics. Driven by a passion for research and development, the team aims to offer hope to patients suffering from severe diseases. The Chairman and Founder of Lin BioScience is Dr.

Tom Lin, who has a successful track record in taking biotech start-up companies public. Dr. Irene Wang, the President and Chief Scientific Officer, brings expertise in preclinical and clinical development.

Miss Yvonne Chen serves as the Chief Operating Officer, utilizing her extensive experience in clinical trial management. Miss Serena Chen, the Chief Financial Officer, ensures efficient management of accounting, finance, and investor relations. With a dedication to improving patient outcomes, Lin BioScience is poised to make a significant impact in the field of drug development